Evidence map›Paper›PMID 16474414›Full record

ArticleBritish journal of pharmacology2006

ROS-sensitive cytochrome P450 activity maintains endothelial dilatation in ageing but is transitory in dyslipidaemic mice.

Stéphane Krummen, Annick Drouin, Marie-Eve Gendron, John R Falck, Eric Thorin

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Age-Dependent Demethylation of Sod2 Promoter in the Mouse Femoral Artery.Oxidative medicine and cellular longevity · 2016
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Endothelial dysfunction in diabetes: multiple targets for treatment.Pflugers Archiv : European journal of physiology · 2010
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Stéphane KrummenDépartement de chirurgie, Institut de Cardiologie de Montréal, Centre de Recherche, 5000 rue Bélanger, Montréal, Québec, Canada H1T 1C8.
Annick Drouin
Marie-Eve Gendron
John R Falck
Eric Thorin
Montreal Heart Institute · CAThe University of Texas Southwestern Medical Center · US

Funding

Novel Eicosanoids: Synthesis and FunctionR01GM031278 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI FALCK, JOHN R. · 1985 to 2012
$4.7M
NIGMS NIH HHS GM31278NIGMS NIH HHS R01 GM031278
6 · The paper itself

Abstract

Risk factors for cardiovascular diseases (CVD) have been proposed to accelerate the vascular endothelial dysfunction that develops during the normal ageing process. The objective of this work was to study the impact of dyslipidaemia (DL) on the dilatory efficacy of the non-NO/non-PGI2 endothelium-derived hyperpolarising factor (EDHF) through maturation and ageing. We isolated and pressurised (80 mmHg) gracilis arterial segments from 3, 12 and 20-month-old (m/o) DL mice expressing the human apolipoprotein B-100 and wild-type (WT) C57BL/6 mice. EDHF-dependent dilatations to acetylcholine (ACh) were measured in the presence of L-NNA (100 microM, NOS inhibitor) and indomethacin (INDO; 10 microM, COX inhibitor). Data are expressed as mean+/-s.e.m.EDHF-mediated maximal dilatation of arteries isolated from WT mice declined by 44% with ageing, from 86+/-3% at 3 months to 66+/-8% at 12 and 48+/-4% at 20 months of age (P<0.05). This decline was magnified by DL to 73%, characterised by an early increased efficacy at 3 m/o (95+/-2%, P<0.05) and a worsening of the dysfunction at 20 m/o (26+/-2%, P<0.05). 17-Octadecynoic acid (17-ODYA), a cytochrome P450/epoxygenase inhibitor, reduced by 56% (P<0.05) ACh-induced EDHF-dependent dilatation of arteries isolated from 3 m/o DL--but not WT--mice, an effect of 17-ODYA disappearing in older DL mice. 17-ODYA, however, reduced (P<0.05) ACh-induced EDHF-dependent dilatation in arteries isolated from 12 m/o WT mice by 35% and from 20 m/o WT mice by 31% (P<0.05). Reactive oxygen species production was increased in arteries isolated from 12 m/o DL mice. The antioxidant N-acetyl-L-cystein (NAC) restored the 17-ODYA-sensitive responses in arteries isolated from 12 - but not 20 - m/o DL mice (84+/-3% from an E(max) of 57+/-8%; P<0.05). NAC did not affect the dilatation of arteries isolated from WT mice. Our data suggest that the decline in EDHF-dependent dilatation is hastened by DL despite the early expression of a 17-ODYA-sensitive pathway increasing the efficacy of the non-NO/non-PGI2 endothelium-dependent dilatation. Acute free radical production contributes to the endothelial dysfunction in the presence of DL only, by abrogating this latter pathway. This 17-ODYA-sensitive pathway, however, appears in 12 m/o WT mice and remains active at 20 m/o.

Indexed as

AgingAcetylcholineAnimalsCytochrome P-450 Enzyme SystemDyslipidemiasEndothelium-Dependent Relaxing FactorsEndothelium, VascularFatty Acids, UnsaturatedGene Expression RegulationIntermediate-Conductance Calcium-Activated Potassium ChannelsMiceOxidative StressPotassium Channels, Inwardly RectifyingReactive Oxygen SpeciesSmall-Conductance Calcium-Activated Potassium ChannelsSodium-Potassium-Exchanging ATPase17-octadecynoic acidAcetylcholineCytochrome P-450 Enzyme SystemEndothelium-Dependent Relaxing FactorsFatty Acids, UnsaturatedIntermediate-Conductance Calcium-Activated Potassium ChannelsPotassium Channels, Inwardly RectifyingReactive Oxygen SpeciesSmall-Conductance Calcium-Activated Potassium ChannelsSodium-Potassium-Exchanging ATPase

Identifiers

PMID16474414
PMCPMC1760710
OpenAlexW2091990262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.